CAPR - NASDAQ
Capricor Therapeutics, Inc.
$27.64
+1.1%Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
At a Glance
Live SnapshotCapricor Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Capricor Therapeutics, Inc. Cash Flow Statement
CAPR • NASDAQ
| Capricor Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-105B | -40.5M | -22.3M | -29M | -20M | -13.7M | -7.6M | -15.2M | 2.4M | -18.8M | -12.9M | -6.2M | -8.9M | -1.9M | -4.9M | -6M | -7.9M | -13.1M | -10.3M | -61.4K | |
1.9B | 1.4M | 1.1M | 533.1K | 245.7K | 143.9K | 172K | 157.7K | 144.2K | 125.7K | 110.9K | 41.9K | 26.9K | 6.3K | 7.5K | 12.9K | 159.6K | 113.3K | 27K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -310.3K | -325.9K | 0.0 | 0.0 | 0.0 | -2M | -1.6M | -496.9K | -263.6K | -861.2K | 4.9M | 0.0 | -2.2M | -3M | -3.1M | 0.0 | |
17B | 9.8M | 7.4M | 4.5M | 3M | 2M | 701K | 1.7M | 1.7M | 2M | 1.6M | 496.9K | 263.6K | 312.7K | 806.3K | 1.1M | 2.2M | 3M | 3.1M | 0.0 | |
16.4B | 65.5K | -18.2K | 196K | 129.7K | 325.9K | 2.7K | 2.3M | -15.7M | 3.5M | 1.6M | 496.9K | 2.2M | 312.7K | -4.9M | 106.8K | 2.2M | 3M | 4M | 4.2K | |
12.2M | -10.8M | -11.8M | 28.7M | 182.3K | 1.5M | -55.3K | -554.6K | -2.9M | -583K | 356K | 6.6M | 538.4K | -64.1K | -579.8K | 470.2K | -352.5K | -668.7K | 880.2K | 1.6K | |
-69.8B | -40M | -25.6M | 4.9M | -16.8M | -10.1M | -6.8M | -13.9M | -14.2M | -15.8M | -10.8M | 958.6K | -6.1M | -2.2M | -4.6M | -4.3M | -5.8M | -10.6M | -5.4M | -55.6K | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-2.9B | -1.5M | -2M | -3.4M | -1.2M | -547.6K | (0.0) | -316.5K | -32.2K | -193.7K | -151.2K | -186.4K | -109.3K | -13.4K | -2K | -2.2K | -36.7K | -92.6K | -288.9K | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -6M | (0.0) | (0.0) | (0.0) | (1.8M) | (21.5M) | (0.0) | -53.2K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-151.4B | -208.4M | -97.4M | -114.2M | (0.0) | -6.1M | -6M | -18M | -19M | -18M | -18M | (0.0) | -227K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
260.6B | 93.8M | 104.6M | 82.5M | 0.0 | 12.1M | 3M | 23M | 24M | 13M | 10M | 327.5K | 4.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-8.8B | 0.0 | 0.0 | 0.0 | 0.0 | 6M | 0.0 | 5M | 5M | -1.8M | -21.5M | 327.5K | 53.9K | -4.3M | 0.0 | 0.0 | 2.5K | -47.3M | -228.8K | 0.0 | |
(97.5B) | -116.2M | (5.1M) | -35.1M | -1.2M | (5.4M) | -3M | (4.7M) | (5M) | -5.2M | -8.1M | (141K) | (3.8M) | -4.3M | -2K | -2.2K | -34.2K | -92.6K | -288.9K | (0.0) | |
FINANCING ACTIVITIES | ||||||||||||||||||||
248.9M | 152.3M | 25.5M | 4.8M | 20.2M | 27.3M | 9.2M | 6.7M | 11.1M | 13.9M | 16.4M | 0.0 | 0.0 | 1.2M | 2.3M | 4.5M | 3.3M | 0.0 | 19.9M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 318.2K | 0.0 | 0.0 | 500K | 4.8M | 0.0 | 5.2M | 3.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -193.0 | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
248.6B | 450.2K | 64.6K | 70.3K | 50.6K | 5.7M | 3.2K | 139.1K | 6.6K | 14K | 45.5K | 4.8K | 0.0 | 0.0 | 13.7K | 6.2K | 217.5K | 0.0 | 0.0 | 0.0 | |
248.9B | 152.8M | 25.6M | 4.9M | 20.2M | 33.4M | 9.2M | 6.9M | 11.6M | 18.6M | 16.5M | 5.2M | 3.9M | 1.2M | 2.3M | 4.5M | 3.5M | 0.0 | 19.9M | 55.3K | |
CASH FLOW SUMMARY | ||||||||||||||||||||
276.6B | -3.4M | 5.1M | -25.3M | 2.2M | 28.8M | -645.8K | -2.3M | 2.3M | -2.4M | -2.5M | 6.3M | 1.6M | -992.5K | -2.3M | 202.4K | -2.3M | -10.7M | 14.2M | 0.0 | |
11.3B | 14.7M | 9.6M | 34.9M | 32.7M | 3.9M | 4.5M | 6.9M | 4.6M | 5.6M | 8M | 1.7M | 170.1K | 1M | 3.4M | 3.2M | 5.5M | 16.2M | 2M | 281.0 | |
287.8B | 11.3M | 14.7M | 9.6M | 34.9M | 32.7M | 3.9M | 4.5M | 6.9M | 3.2M | 5.6M | 8M | 1.7M | 46.7K | 1M | 3.4M | 3.2M | 5.5M | 16.2M | 281.0 | |
-72.7B | -41.5M | -27.6M | 1.6M | -18M | -10.6M | -6.8M | -14.2M | -14.3M | -16M | -11M | 772.1K | -6.3M | -2.2M | -4.7M | -4.3M | -5.8M | -10.7M | -5.7M | -55.6K |
SEC Filings
CAPR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | June 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 05, 2025 | December 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 03, 2025 | December 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 03, 2025 | December 03, 2025 | 2025 |
Related Guides
Continue your CAPR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.